RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$2.89-1.87%
Price as of Jul 20, 2026
RXRX profitability
Recursion Pharmaceuticals, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -34.4%
- EBITDA margin
- -723.3%
- EBIT margin
- -882.9%
- Net margin
- -844.5%
- Free cash flow margin
- -491.6%
Returns
- Return on equity
- -54.6%
- Return on assets
- -41.8%
- Return on invested capital
- -53.3%
- Asset turnover
- 0.05x
Cash efficiency
- Cash from operations
- -$321.0M
- Cash per share
- $1.24
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.